Treatment with IO agents, such as anti-PD-L1 and OX40+4-1BB agonists, that could enhance and enable pre-existing T cells in the immune-inflamed ‘warm’ MC38-CEA tumor resulted in decreased tumor burden. Here, TNFRSF4 is linked to neoplasm.